# Methylphenidate

## Concerta ER 27mg

| TAH Drug Code      | [OCON2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCON2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention deficit hyperactivity disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | Attention deficit disorder : (Child over 6 years and adult) Concerta: 27mg(1 TAB) QD. ( maximum for Child: 54 mg/day; maximum for adult : 72 mg/day )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Concomitant use of MAOIs， or use within 14 days of MAOI discontinuation. Glaucoma. Hypersensitivity to methylphenidate or other components of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | Common: Increased blood pressure， Palpitations (3.1%)， Tachycardia (4.8-7%)， Diaphoresis (5.1%)， Weight decreased (3-6.5%)， Abdominal pain， Decrease in appetite (19-27%)， Indigestion (2.2%)， Nausea (6-12.8%)， Upper abdominal pain (6.2-9%)， Vomiting (1.7-9%)， Xerostomia (14%)， Dizziness (1.9-6.7%.)， Headache (10-22.2%)， Insomnia (2.8-41%)， Anxiety (8.2%)， Depression (1.7-3.9%)， Hallucinations， Irritability (5.8-6%)， Labile affect (Adult， 1.4% ; pediatric， 22%). Serious: Myocardial infarction， Peripheral vascular disease， Sudden cardiac death， Decreased body growth， Gastrointestinal obstruction， With preexisting severe gastrointestinal narrowing and use of controlled-release formulations， Abnormal liver function， Cerebral artery occlusion， Cerebral hemorrhage， Cerebrovascular accident， Gilles de la Tourette's syndrome， Worsening， Lowered convulsive threshold， Seizure， Angle-closure glaucoma， Blurred vision (1.7%)， Aggressive behavior (1.7%.)， Mania， Psychotic disorder， Priapism， Drug abuse， Substance dependence. |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/methylphenidate-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

## Methydur 22mg sustained release

| TAH Drug Code      | [OMTD22](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMTD22)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention deficit hyperactivity disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | Take once daily， within 20 minutes after breakfast， with water. Do not chew， split， or crush the capsules. For patients not previously taking Methylphenidate or other stimulants: 22mg/day. If the desired effect is not achieved: increase dose by 11mg every 7 days (max 44mg/day).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Concomitant use of MAOIs， or use within 14 days of MAOI discontinuation. Hypersensitivity to methylphenidate or other components of the product. Anxiety and tension， mental agitation， siblings who have had convulsions， family members or individuals who have been diagnosed with Tourette’s syndrome， glaucoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Common: Tachycardia (4.8-7%)， Diaphoresis (Adult， 5.1%)， Weight decreased (2.4-12%)， Abdominal pain (Pediatric 4-15%)， Decrease in appetite (2-35%)， Loss of appetite (Adult 1.7% ; pediatric 3.1-9% or greater )， Nausea (2.4-12.8%)， Vomiting (1.7-9%)， Xerostomia (3-14%)， Dizziness (Adult 6.7%; pediatric 1.9-3%)， Headache (Adult 22.2% ; pediatric 2.4-19%)， Insomnia (2.8-41%)， Anxiety (Adult 8.2%)， Depression (Adult 1.7-3.9%)， Irritability (5.8-10%). Serious: Myocardial infarction， Raynaud's phenomenon， Sudden cardiac death， Decreased body growth， Gastrointestinal obstruction， With preexisting severe gastrointestinal narrowing and use of controlled-release formulations， Abnormal liver function， Cerebral artery occlusion， Cerebral hemorrhage， Cerebrovascular accident， Lowered convulsive threshold， Seizure， Blurred vision (>1.7-2%)， Aggressive behavior (1.7-2.4%)， Mania， Psychotic disorder， Priapism， Drug abuse， Substance dependence. |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/methylphenidate-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Ritalin 10mg

| TAH Drug Code      | [ORIT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORIT)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention-deficit/hyperactivity disorder Major depressive disorder in medically ill， palliative care， terminal illness， or elderly patients Narcolepsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Attention-deficit/hyperactivity disorder: Adults: Initial: 10 to 20 mg/day in 2 divided doses before breakfast and lunch; may increase based on response and tolerability in 5 to 10 mg increments at weekly or greater intervals up to a maximum dose of 60 mg/day in 2 to 3 divided doses. Children ?6 years and Adolescents: Initial: Oral: 2.5 to 5 mg twice daily administered before breakfast and lunch; increase by 5 to 10 mg/day at weekly intervals; some patients may require 3 doses/day (eg， additional dose after school); usual maximum daily dose: 60 mg/day， not to exceed 2 mg/kg/day; however， some patients weighing >50 kg may require and tolerate daily doses up to 100 mg/day with frequent monitoring. Narcolepsy: Adults: Initial: 10 mg twice daily before breakfast and lunch; may increase dose based on response and tolerability in increments of 5 to 10 mg at intervals of ?1 week up to a maximum dose of 60 mg/day in 2 to 3 divided doses with the last dose given no later than about 3:00 PM. Children ?6 years and Adolescents: Initial: 5 mg twice daily given before breakfast and lunch; increase by 5 to 10 mg/day increments at weekly intervals; 2 to 3 times per day; maximum daily dose: 60 mg/day (in 2 to 3 divided doses).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | - Allergy to methylphenidate or excipients - Anxiety， nervousness， agitation - Hyperthyroidism - Cardiovascular diseases (severe hypertension， angina， arterial occlusion， heart failure， significant congenital heart disease， cardiomyopathy， myocardial infarction， life-threatening arrhythmias， ion channel disorders) - Use of MAO inhibitors or within 2 weeks of discontinuation (risk of hypertensive crisis) - Glaucoma - Pheochromocytoma - Tourette’s syndrome or family history of Tourette’s                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | >10%: Gastrointestinal: Decreased appetite (2% to 26%)， nausea (2% to 13%)， xerostomia (oral: 3% to 14%) Nervous system: Headache (2% to 22%， including migraine; tension headache: oral: 1%)， insomnia (including initial insomnia; oral: 2% to 33%; transdermal: 6% to 13%)， irritability (2% to 11%) 1% to 10%: Cardiovascular: Increased blood pressure (?2%)， increased diastolic blood pressure (oral: 7%)， palpitations (3%)， tachycardia (oral: 5%; transdermal: ?1%) Dermatologic: Excoriation of skin (oral: 4%)， hyperhidrosis (oral: 5%)， skin rash (oral: 2%) Endocrine & metabolic: Decreased libido (oral: 2%)， weight loss (2% to 9%) Gastrointestinal: Abdominal pain (5% to 7%)， anorexia (2% to 9%)， bruxism (oral: 2%)， constipation (oral: 1%)， diarrhea (oral: 4%)， dyspepsia (oral: 2%)， motion sickness (oral: 2%)， upper abdominal pain (oral: 4% to 9%)， vomiting (2% to 10%) Genitourinary: Dysmenorrhea (oral: 2%) Hematologic & oncologic: Bruise (oral: 3%) Nervous system: Aggressive behavior (oral: 2%)， agitation (oral: 2%)， anxiety (oral: 8%)， confusion (oral: 1%)， depressed mood (oral: 4%)， depression (2%)， dizziness (2% to 7%)， emotional lability (1% to 9%)， fatigue (3%)， hypertonia (oral: 2%)， jitteriness (oral: 4%)， lack of emotion (oral: 2%)， nervousness (3%) paresthesia (1%)， psychomotor agitation (oral: 5%)， restlessness (oral: 3%)， sedated state (oral: 1%)， tension (oral: 1%)， tic disorder (1% to 9%)， tremor (oral: 3%)， vertigo (oral: 2%) Neuromuscular & skeletal: Back pain (oral: 3%) Ophthalmic: Blurred vision (2%)， eye pain (oral: 2%) Respiratory: Cough (oral: 2%)， nasopharyngitis (oral: 3%)， oropharyngeal pain (oral: 1% to 2%)， streptococcal pharyngitis (oral: 3%)， upper respiratory tract infection (oral: 2%) Miscellaneous: Fever (oral: 2%) <1%: Dermatologic: Contact hypersensitivity (transdermal) |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/methylphenidate-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

## RITALIN LA 20mg

| TAH Drug Code      | [ORIT2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORIT2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention deficit hyperactivity disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Children >= 6 years (immediate-release Tablets) Initially 10mg. Dose adjustment can be based on the observed tolerance and therapeutic effect with gradual increments of 10 mg weekly. maximum: 40 mg/day. Adult: 20 mg QD initially.maximum: 60 mg/day.Ritalin LA sustained action capsules can be adjusted by increasing the dosage by 10 mg weekly. Immediate-release Tablets convert to extended-release Tablets: 5mg methylphenidate BID (immediate-release TABlets) is equivalent to 10mg methylphenidate(extended release Tablets) QD.10mg methylphenidate BID (immediate-release Tablets) is equivalent to 20mg methylphenidate(extended release Tablets) QD. 15mg methylphenidate BID (immediate-release TABlets) is equivalent to 30mg methylphenidate(extended release Tablets) QD. 20mg methylphenidate BID (immediate-release Tablets) is equivalent to 40mg methylphenidate(extended release Tablets) QD.                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Those allergic to methylphenidate or other excipients. Anxiety， nervousness， excited， hyperthyroidism. People with cardiovascular disease， including severe hypertension， angina， atretic heart disease， heart failure， congenital heart disease with significant hemodynamic changes， cardiomyopathy， myocardial infarction， potentially fatal arrhythmias， and ion channel pathologies (due to Diseases caused by abnormal ion channel function). Patients who are treated with monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping MAOIs are at risk of developing hypertensive crisis. Glaucoma， Pheochromocytoma， Tics. Patients diagnosed with Tourette’s syndrome or those with a family history of the disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common: Tachycardia (4.8-7%)， Diaphoresis (Adult， 5.1%)， Weight decreased (2.4-12%)， Abdominal pain (Pediatric， 4-15%)， Decrease in appetite (2-35%)， Loss of appetite (Adult， 1.7% ; pediatric， 3.1-9% or greater )， Nausea (2.4-12.8%)， Vomiting (1.7-9%)， Xerostomia (3-14%)， Dizziness (Adult， 6.7%; pediatric， 1.9-3% .)， Headache (Adult， 22.2% ; pediatric， 2.4-19%)， Insomnia (2.8-41%)， Anxiety (Adult， 8.2%)， Depression (Adult， 1.7-3.9%)， Irritability (5.8-10%) Serious: Myocardial infarction， Peripheral vascular disease， Raynaud's phenomenon， Sudden cardiac death， Decreased body growth， Gastrointestinal obstruction， With preexisting severe gastrointestinal narrowing and use of controlled-release formulations， Abnormal liver function， Cerebral artery occlusion， Cerebral hemorrhage， Cerebrovascular accident， Gilles de la Tourette's syndrome， Worsening， Lowered convulsive threshold， Seizure， Tic (Pediatric， 1-9%)， Angle-closure glaucoma， Blurred vision (1.7-2% or greater )， Raised intraocular pressure， Aggressive behavior (1.7-2.4%)， Mania， Psychotic disorder， Priapism， Drug abuse， Substance dependence |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/methylphenidate-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## Toncus 36mg extended release

| TAH Drug Code      | [OTON36](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OTON36)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention deficit hyperactivity disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Initial and Dosage Range Recommendations for First-time Users: - Children (6-12 years): 18 mg/day; dosage range is 18-54 mg/day. - Adolescents (13-17 years): 18 mg/day; dosage range is 18-54 mg/day (do not exceed 2 mg/kg/day). - Adults (18-65 years): 18 or 36 mg/day; dosage range is 18-54 mg/day. For Patients Currently Using Methylphenidate: Patients currently taking Methylphenidate 10-60 mg/day， two or three times a day， should transition to Methylphenidate doses based on current regimens and clinical judgment. The maximum recommended daily dose is 54 mg. The converted dose should not exceed 54 mg/day. Previous Methylphenidate Daily Dose: Initial Dose of Methylphenidate 5 mg twice or three times daily: 18 mg every morning 10 mg twice or three times daily: 36 mg every morning 15 mg twice or three times daily: 54 mg every morning 20 mg twice or three times daily: 54 mg every morning                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to methylphenidate or other components of the product. Concomitant use of MAOIs， or use within 14 days of MAOI discontinuation. Patients who are markedly anxious， tense， or agitated. Patients with glaucoma. Patients with motor tics or a family history of Tourette’s syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Tachycardia (4.8-7%)， Diaphoresis (Adult， 5.1%)， Weight decreased (2.4-12%)， Abdominal pain (Pediatric， 4-15%)， Decrease in appetite (2-35%)， Loss of appetite (Adult， 1.7% ; pediatric， 3.1-9% or greater)， Nausea (2.4-12.8%)， Vomiting (1.7-9%)， Xerostomia (3-14%)， Dizziness (Adult， 6.7%; pediatric， 1.9-3% .)， Headache (Adult， 22.2% ; pediatric， 2.4-19%)， Insomnia (2.8-41%)， Anxiety (Adult， 8.2%)， Depression (Adult， 1.7-3.9%)， Irritability (5.8-10%). Serious: Myocardial infarction， Peripheral vascular disease， Raynaud's phenomenon， Sudden cardiac death， Decreased body growth， Gastrointestinal obstruction， With preexisting severe gastrointestinal narrowing and use of controlled-release formulations， Abnormal liver function， Cerebral artery occlusion， Cerebral hemorrhage， Cerebrovascular accident， Gilles de la Tourette's syndrome， Worsening， Lowered convulsive threshold， Seizure， Tic (Pediatric， 1-9%)， Angle-closure glaucoma， Blurred vision (1.7-2% or greater)， Raised intraocular pressure， Aggressive behavior (1.7-2.4%)， Mania， Psychotic disorder， Priapism， Drug abuse， Substance dependence. |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| More Info          | [UpToDate](https://www.uptodate.com/contents/methylphenidate-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

